SABS Stock Analysis: Buy, Sell, or Hold?
SABS - SAB Biotherapeutics, Inc. Common Stock
$3.78
-0.07 (-1.82%)
▼
5d:
-3.82%
30d:
-7.8%
90d:
+0.0%
HOLD
MODERATE Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 08, 2026
Get Alerted When SABS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SABS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: SABS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: SABS is currently trading at $3.78, which is considered slightly low relative to its 30-day fair value range of $3.70 to $4.16.
Technical Outlook: Technically, SABS is in a uptrend. The price is currently testing key support at $3.69. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SABS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $9.50 (+151.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SABS is in a uptrend. The price is currently testing key support at $3.69. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SABS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $9.50 (+151.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$3.70 -
$4.16
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 151.3% below Wall St target ($9.50)
Fair Price Analysis
30-Day Fair Range
$3.70 -
$4.16
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$3.69
Resistance Level
$4.18
Current Trend
Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.45
Wall Street Target
$9.50
(+151.3%)
Revenue Growth (YoY)
-62.4%
Earnings Growth (YoY)
-60.0%
Share & Embed Analysis
Last updated: March 30, 2026 6:10 PM ET
Data refreshes hourly during market hours. Next update: 7:10 PM
Data refreshes hourly during market hours. Next update: 7:10 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SABS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 48 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 67 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 57 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$109 | 45 HOLD |
